NCT04675463 - The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

June 30, 2023

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

BGF Inhalation Aerosphere

Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time

DRUG

GFF Inhalation Aerosphere

Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time

Trial Locations (1)

Guangzhou Institute of Respiratory Diseases, Guangzhou